In vivo biological effects of ATRA in the treatment of AML

Expert Opinion on Investigational Drugs

Volumn 17, Issue 11, 2008, Pages 1623-1633

  Ryningen, Anita ^a   Stapnes, Camilla ^a   Paulsen, Kristin ^a   Lassalle, Philippe ^b   Gjertsen, Björn Tore ^a   Bruserud, Øystein ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Acute myelogenous leukaemia; All trans retinoic acid; Cell cycle regulation; Cytokines; In vivo treatment

Indexed keywords

ANGIOPOIETIN 2; CELL MARKER; ENDOCAN; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN P21; RETINOIC ACID; SYNAPTOTAGMIN I; THEOPHYLLINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 2; UNCLASSIFIED DRUG; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA CELL; LOW DRUG DOSE; MALE; MONOTHERAPY;

AGED; AGED, 80 AND OVER; BIOLOGY; CELL PROLIFERATION; CELL SEPARATION; CELL SHAPE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTION FACTORS; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 54949137356     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.11.1623     Document Type: Article

References (46)

1. Lo-Coco F, Ammatuna E. The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. Hematol Am Soc Hematol Educ Program 2006;514:156-61
2. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999;94(4):1192-200
3. Dimberg A, Bahram F, Karlberg I, et al. Retinoic acid-induced cell cycle arrest of human myeloid cell lines is associated with sequential down-regulation of c-Myc and cyclin E and posttranscriptional up-regulation of p27(Kip1). Blood 2002;99(6):2199-206
4. Hsu CA, Rishi AK, Su-Li X, et al. Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway. Blood 1997,89(12):4470-9
5. Kim KJ, Kim HH, Kim JH, et al. Chemokine stromal cell-derived factor-1 induction by C/EBPbera activation is associated with all-trans-retinoic acid-induced leukemic cell differentiation. J Leukoc Biol 2007;82(5):1332-9
6. Pession A, Martino V, Tonelli R, et al. MLL-AF9 oncogene expression affects cell growth but not terminal differentiation and is downregulated during monocyte-macrophage maturation in AML-M5 THP-1 cells. Oncogene 2003;22(54):8671-6
7. Milligan DW. Wheatley K, Littlewood T, et al. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood 2006;107(12):4614-22
8. Estey EH, Thall PF, Pierce S, et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/-granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999;93(8):2478-84
9. Belhabri A, Thomas X, Wattel E, et al. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial. Hematol J 2002;3(1):49-55
10. Schlenk RF, Frohling S, Hartmann F, et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 2004;18(11):1798-803
11. Schlenk R, Dohner K, Kneba M, et al. The genotype NPM1 mut/FLT3-ITDneg is a highly significant predictive factor for response to therapy with all-trans retinoic acid in acute myeloid leukemia - Results from AMLSG Trial AML HD98B. ASH Annual Meeting Abstracts. Blood 2007;110(11):297a
12. Tsaur G, Ivanova A, Nasedkina T, et al. Molecular remission in MLL/ AF4-positive infant leukemia treated with the all trans-retinoic acid based MLL-baby protocol. ASH Annual Meeting Abstracts. Blood 2007;100(11):4254a
13. Fechina L, Tsaur G, Saveliev L, et al. Contribution of all-trans retinoic acid to improved early relapse-free outcome in infant acute lymphoblastic leukemia comparing to the chemotherapy alone. ASH Annual Meeting Abstracts. Blood 2007;110(11):2828a
14. Trus MR, Yang L, Suarez Saiz F, et al. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia 2005;19(7):1161-8
15. Iijima K, Honma Y, Niitsu N. Granulocytic differentiation of leukemic cells with t(9;11)(p22;q23) induced by all-trans-retinoic acid. Leuk Lymphoma 2004;45(5):1017-24
16. Bruserud O, Stapnes C, Tronstad KJ, et al. Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert Opin Ther Targets 2006;10(1):51-68
17. Bruserud O, Stapnes C, Ersvaer E, et al. Histone deacetylase inhibitors in cancer treatment: a review of clinical toxicity and immunosuppresion, effects on normal hematopoiesis and modulation of gene expression in cancer cells. Curr Pharm Biotechnol 2007;8(6):388-400
18. Fenu S, Nervi C, Chierichini A, et al. Sequential treatment with low doses of retinoic acid (LOATRA) +/- valproic acid (VPA) followed by low doses ARAC(LODAC) in elderly acute myeloid leukaemia (AML) preliminary clinical and biological results. Heamatologica 2008;93(s1):208
19. Stapnes C, Ryningen A, Gjertsen BT, Bruserud O. Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia. Acta Oncol 2006;45(3):346-9
20. Bruserud O, Gjertsen BT, Von Volkman HL. In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines. J Hematother Stem Cell Res 2000;9(6):923-32
21. Bruserud O, Gjertsen BT Foss B, Huang TS. New strategies in the treatment of acute myelogenous leukemia (AML): in vitro. culture of aml cells - the present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells 2001;19(1):1-11
22. Bruserud O, Ryningen A, Wergeland L, et al. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica 2004;89(4):391-402
23. Stapnes C, Ryningen A, Hatfield K, et al. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. Int J Onool 2007;31(6):1529-38
24. Bechard D, Meignin V, Scherpereel A, et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 2000;37(5):417-25
25. Dorfman DM, Wilson DB, Bruns GA, Orkin SH. Human transcription factor GATA-2. Evidence for regulation of preproendothelin-1 gene expression in endothelial cells. J Biol Chem 1992;267(2):1279-85
26. Feng Z, Porter AG. NF-kappaB/Rel proteins are required for neuronal differentiation of SH-SY5Y neuroblastoma cells. J Biol Chem 1999;274(43):30341-4
27. Segars JH, Nagata T, Bours V, et al. Retinoic acid induction of major histocompatibility complex class I genes in NTera-2 embryonal carcinoma cells involves induction of NF-kappa B (p50-p65) and retinoic acid receptor beta-retinoid X receptor beta heterodimers. Mol Cell Biol 1993;13(10):6157-69
28. Farina AR, Masciulli MP, Tacconelli A, et al. All-trans-retinoic acid induces nuclear factor kappaB activation and matrix metalloproteinase-9 expression and enhances basement membrane invasivity of differentiation-resistant human SK-N-BE 9N neuroblastoma Cells. Cell Growth Differ 2002;13(8):343-54
29. Perry C, Soreq H. Transcriptional regulation of erythropoiesis. Fine tuning of combinatorial multi-domain elements. Eur J Biochem 2002;269(15):3607-18
30. Lugus JJ, Chung YS, Mills JC, et al. GATA2 functions at multiple steps in hemangioblast development and differentiation. Development 2007;134(2):393-405
31. Ezoe S, Matsumura I, Nakata S, et al. GATA-2/estrogen receptor chimera regulates cytokine-dependent growth of hematopoietic cells through accumulation of p21(WAF1) and p27(Kip1) proteins. Blood 2002;100(10):3512-20
32. Shimizu R, Yamamoto M. Gene expression regulation and domain function of hematopoietic GATA factors. Semin Cell Dev Biol 2005;16(1):129-36
33. Bruserud O, Ryningen A, Olsnes AM, et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007;92(3):332-41
34. Hatfield K, Hovland R, Oyan AM, et al. Release of Angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia 2007;22(2):287-93
35. Schliemann C, Bieker R, Thoennissen N, et al. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia 2007;21(9):1901-6
36. Loges S, Heil G, Bruweleit M, et al. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol 2005;23(6):1109-17
37. Schliemann C, Bieker R, Padro T, et al. Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica 2006;91(9):1203-11
38. Shimamoto T, Ohyashiki K, Ohyashiki JH, et al. The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia. Blood 1995;86(8):3173-80
39. Rice AM, Holtz KM, Karp J, et al. Analysis of the relationship between Scl transcription factor complex protein expression patterns and the effects of LiCl on ATRA-induced differentiation in blast cells from patients with acute myeloid leukemia. Leuk Res 2004;28(11):1227-37
40. Wieser R, Volz A, Vinatzer U, et al. Transcription factor GATA-2 gene is located near 3q21 breakpoints in myeloid leukemia. Biochem Biophys Res Commun 2000;273(1):239-45
41. Lahortiga I, Vazquez I, Agirre X, et al. Molecular heterogeneity in AML/ MDS patients with 3q21q26 rearrangements. Genes Chromosomes Cancer 2004;40(3):179-89
42. Martelli M, Pettirossi V, Manes N, et al. Selective silencing of the NPM1 mutant protein and apoptosis induction upon ATRA in vitro treatment of AML cells carrying NPM1 mutations. Haematologica 2008;93(s1):7
43. Kini AR, Peterson LA, Tallman MS, Lingen MW. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood 2001;97(12):3919-24
44. Cho DH, Choi YJ, Jo SA, et al. Retinoic acid decreases nitric oxide production in endothelial cells: a role of phosphorylation of endothelial nitric oxide synthase at Ser1179. Biochem Biophys Res Commun 2005;326(4):703-10
45. Marchetti M, Vignoli A, Bani MR, et al. All-trans retinoic acid modulates microvascular endothelial cell hemostatic properties. Haematologica 2003;88(8):895-905
46. Axel DI, Frigge A, Dittmann J, et al. All-trans retinoic acid regulates proliferation, migration, differentiation, and extracellular matrix turnover of human arterial smooth muscle cells. Cardiovasc Res 2001;49(4):851-62